A Phase Ib dose-escalation study to evaluate safety and tolerability of the addition of the aminopeptidase inhibitor tosedostat (CHR-2797) to paclitaxel in patients with advanced solid tumours

BACKGROUND: This Phase Ib dose-escalating study investigated safety, maximum tolerated dose (MTD), dose-limiting toxicity (DLT), pharmacokinetics (PK) and clinical antitumour activity of tosedostat (CHR-2797), an orally bioavailable aminopeptidase inhibitor, in combination with paclitaxel. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: van Herpen, C M L, Eskens, F A L M, de Jonge, M, Desar, I, Hooftman, L, Bone, E A, Timmer-Bonte, J N H, Verweij, J
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2010
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2990605/
https://www.ncbi.nlm.nih.gov/pubmed/20877350
http://dx.doi.org/10.1038/sj.bjc.6605917

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2990605/
https://www.ncbi.nlm.nih.gov/pubmed/20877350
http://dx.doi.org/10.1038/sj.bjc.6605917

Ejemplares similares